Gilead Sciences, Inc. (GILD) Rating Reiterated by Mizuho


's stock had its "buy" rating reaffirmed by investment analysts at Mizuho in a research report issued on Sunday, Marketbeat.com reports. They presently have a $130.00 target price on the biopharmaceutical company's stock.



from Biotech News